论文部分内容阅读
为探讨术后以紫杉醇为基础的联合化疗的治疗效果。 回顾分析了1993～1998年24例原发性输卵管癌的病史资料包括年龄、分期、化疗方案、手术记录、复发及生存情况等。治疗前均经病理确诊。 患者平均年龄63(44～76)岁,其中Ⅰ期4例(17％),Ⅱ期3例(12％),Ⅲ期16例(67％),Ⅳ期1例(4％)。组织学分级,G_24例,G_320例。24例患者中,A组:16例(67％)实施了理想减瘤术(术后残留灶<1 cm);B组:8例(33％)实施了亚理想减瘤术。术后化疗:紫杉醇+卡铂17例;紫杉醇+顺铂6例;紫杉醇单药1例。中位疗程数5个。术后中位随访时间24(1～73)个月,其中2例死于肿瘤。1年生存率96％。3年生存率为90％。24例患者中位肿瘤无进展生存期27(5～57)个月。A组3年肿瘤无进展生存率为67％(95％CI 45
To explore postoperative paclitaxel-based combination chemotherapy treatment. Retrospective analysis of the history of 24 cases of primary fallopian tube cancer from 1993 to 1998, including age, staging, chemotherapy regimen, surgical records, recurrence and survival. Pathological diagnosis before treatment. The average age of patients was 63 (44-76) years old, including 4 cases (17%) in stage Ⅰ, 3 cases (12%) in stage Ⅱ, 16 cases (Ⅲ) in stage Ⅲ and 1 case (4%) in stage Ⅳ. Histological grade, G_24 cases, G_320 cases. Of the 24 patients, group A: ideal reduction surgery (residual lesions <1 cm) was performed in 16 patients (67%); subgroup B: 8 patients (33%) underwent sub-ideal subtraction surgery. Postoperative chemotherapy: paclitaxel + carboplatin in 17 cases; paclitaxel + cisplatin in 6 cases; paclitaxel alone in 1 case. Median treatment number 5. The median follow-up time was 24 months (range, 1 to 73) months, of which 2 died of tumor. 1-year survival rate of 96%. 3-year survival rate was 90%. Twenty-four patients had a median progression-free survival of 27 (5 to 57) months. Three years of progression-free survival in group A was 67% (95% CI 45)